An oral PCSK9 pill cut LDL 65% and beat every other oral nonstatin drug

Enlicitide, the first PCSK9 inhibitor that comes as a pill rather than an injection, lowered LDL cholesterol by 64.6% in statin-treated adults and outperformed every other oral non-statin cholesterol drug it was tested against, according to the phase 3 CORALreef AddOn trial [s1]. Against the same statin background, ezetimibe cut LDL by 27.8%, bempedoic acid by 6.3%, and the two combined by 36.5% — none of them close [s1].

The result speaks to a specific, common clinical dead end. Many people at high cardiovascular risk cannot get their LDL cholesterol low enough on a statin alone, and the oral options for adding on — ezetimibe, bempedoic acid — are only modestly effective, while the powerful PCSK9 inhibitors have until now required an injection every two weeks or every month. Enlicitide's approval by the FDA in July 2026, covered on this site in the first oral drug in a class that had only ever been injectable, changed the format; CORALreef AddOn is the trial that shows how the pill stacks up against the pills it would replace [s2].

What the trial did

The phase 3, double-blind, active-comparator trial, funded by Merck (MSD), randomised 301 statin-treated adults in a 2:1:1:2 ratio to 20 mg enlicitide (n=101), 180 mg bempedoic acid (n=50), 10 mg ezetimibe (n=50), or bempedoic acid plus ezetimibe (n=100), each once daily for 56 days [s1]. Participants were aged 18 or older with LDL cholesterol of at least 55 mg per decilitre and a prior major atherosclerotic cardiovascular event, or at least 70 mg per decilitre if at intermediate-to-high risk of a first event; their mean age was 64.4 years, 37% were female, and 98% were on a moderate- or high-intensity statin [s1]. The primary endpoint was the mean percentage change in LDL cholesterol from baseline to day 56 [s1].

One design point is worth flagging: the sponsor participated in the study design, data analysis, and manuscript preparation, which the paper discloses [s1]. That is common for industry-run registration trials, and the endpoint — a laboratory LDL measurement in a blinded trial — is about as hard to massage as cardiology endpoints get, but it is the reason the independent value of a trial like this rests on its design and its transparency rather than on the sponsor's word.

What it found

The mean fall in LDL cholesterol from baseline to day 56 was 64.6% with enlicitide (95% CI 60.9 to 68.3), 6.3% with bempedoic acid (95% CI, a reduction of up to 13.5% to a 0.8% rise), 27.8% with ezetimibe (95% CI 23.4 to 32.3), and 36.5% with bempedoic acid plus ezetimibe (95% CI 32.2 to 40.8) [s1]. Enlicitide was statistically superior to each comparator (all P<0.001), and its advantage held for apolipoprotein B and non-HDL cholesterol, two other measures of the artery-clogging particles that track cardiovascular risk more completely than LDL alone [s1]. Bempedoic acid's confidence interval crossing zero is notable — on top of a statin, its added effect in this trial was small and not clearly distinguishable from none [s1]. Of the 301 participants, 298 (99.0%) completed the trial, and the rates of adverse events and of discontinuations for them were similar across the four arms [s1].

The scale of the gap is what makes the trial useful. Enlicitide's 64.6% reduction is not a marginal improvement on the next-best oral option; it is nearly twice the fall of bempedoic acid and ezetimibe combined (36.5%) and more than double ezetimibe alone (27.8%) [s1]. For a patient who remains well above target on a statin plus an oral add-on, that is the difference between reaching a guideline LDL goal and staying short of it — the practical decision the drug was built for. The background context matters too: enlicitide lowered LDL by 60% against placebo in earlier testing, so this head-to-head confirms that the effect survives the harder comparison against active drugs rather than an inert pill [s1].

How to read it

CORALreef AddOn establishes that enlicitide lowers LDL far more than the existing oral add-ons — a genuine gap-filler for patients who will not or cannot use an injection. But two limits define what it does not show. It ran for 56 days and measured cholesterol, not heart attacks or strokes; a lipid reduction is a well-validated stand-in for cardiovascular benefit, but the outcome trials that convert one into the other for enlicitide specifically are still to report [s1]. And the comparators were oral drugs only: the trial does not tell you how the pill compares with the injectable PCSK9 antibodies that already have cardiovascular-outcome evidence behind them. For the broader picture of what these numbers mean, what the cholesterol numbers mean sets the baseline, and the separate problem of lipoprotein(a) — which none of these drugs meaningfully move — runs through the obicetrapib lipoprotein(a) analysis.

What to watch

The decisive questions are outcomes and access: whether enlicitide's large LDL reduction produces the expected drop in cardiovascular events in a dedicated trial, where guidelines place an oral PCSK9 inhibitor relative to the cheaper generic add-ons and the injectable antibodies, and how it is priced — the factor that will decide whether a more effective pill actually reaches the people stuck short of their targets.

This article describes research and is not medical advice. Decisions about cholesterol-lowering treatment are for patients and their treating clinicians.

Sources

• Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial (CORALreef AddOn) — Journal of the American College of Cardiology, published online 30 March 2026
• FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol — U.S. Food and Drug Administration, 17 July 2026